Nomogram for Breast Cancer Brain Metastasis

A nomogram for breast cancer brain metastasis estimates an individual patient’s risk of developing brain metastases using key clinical and tumor characteristics.

Age, years
95-100085-94+1075-84+2265-74+3455-64+4545-54+5535-44+6525-34+7715-24+8810-14+100
Histological grade
1 and 203+25
Receptor status
ER+ or PR+/HER20ER-/HER2-+20HER2++60
Delay between diagnosis and first metastasis, months
72-91+15≥ 9+2054-71+3542-53+4530-41+6022-29+6510-21+700-9+73
Number of non brain metastatic sites
10> 1+35

Indications for Use

Used in patients with metastatic breast cancer without existing brain involvement to estimate individualized risk of developing brain metastases and guide selection for intensified surveillance or prevention‑trial enrollment. Based on validated clinical predictors (age, receptor status, metastatic burden, disease‑free interval) with moderate discrimination (AUC ~0.68–0.74) 1 [Level II evidence]. Helps enrich high‑risk cohorts and inform counseling; not for diagnostic decision making or treatment selection.

Insights & Cautions

Uses clinicopathologic factors (age, subtype, metastatic burden, disease‑free interval) to estimate individual brain‑metastasis risk. Insights: strongest predictors include ER/HER2 negativity and multiple metastatic sites 1; HER2+ and TN subtypes show highest cumulative incidence 2. Cautions: models are retrospective, modest discrimination (AUC ~0.68–0.74), risk of overestimation in modern HER2‑targeted era, and not validated for screening or altering surveillance.